The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Qiagen NV shares valued at $1,150,000 were purchased by Sackers Roland on Sep 11 ’24. At $46.00 per share, Sackers Roland acquired 25,000 shares.
As published in a research note from Redburn Atlantic on April 04, 2025, Qiagen NV [QGEN] has been rated down from a Buy to a Neutral. Analysts at Robert W. Baird downgraded the stock from ‘”an Outperform”‘ to ‘”a Neutral”‘ outlook in a report released in mid February. As of January 06, 2025, Morgan Stanley has decreased its “an Overweight” rating to a “an Equal-weight” for QGEN. Earlier on December 10, 2024, Jefferies upgraded its rating. Their new recommendation was “a Buy” for QGEN stock which previously was a “a Hold”.
Analyzing QGEN Stock Performance
During the last five days, there has been a drop of approximately -0.28%. Over the course of the year, Qiagen NV shares have dropped approximately -4.25%. Shares of the company reached a 52-week high of $49.30 on 01/22/25 and a 52-week low of $37.63 on 03/04/25. A 50-day SMA is recorded $40.42, while a 200-day SMA reached $43.96.
Support And Resistance Levels for Qiagen NV (QGEN)
According to the 24-hour chart, there is a support level at 42.23, which, if violated, would cause prices to drop to 41.82. In the upper region, resistance lies at 42.89. The next price resistance is at 43.14. RSI (Relative Strength Index) is 55.64 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.27, which suggests the price will decrease in the coming days. Percent R is at 23.99%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
